{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:38Z","timestamp":1792001918129,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:00:00Z","timestamp":1703980800000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejca.2022.12.005","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T11:22:22Z","timestamp":1670844142000},"page":"117-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"Jordi","family":"Remon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-431X","authenticated-orcid":false,"given":"Florit","family":"Marcuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-8465","authenticated-orcid":false,"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Hochstenbag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.12.005_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2022.02.001","article-title":"Trends in incidence and survival of patients with thymic epithelial tumor in a high-incidence Asian Country: analysis of the Korean Central Cancer Registry 1999 to 2017","volume":"17","author":"Shin","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib3","doi-asserted-by":"crossref","first-page":"S1078","DOI":"10.1016\/j.annonc.2020.08.1442","article-title":"Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)","volume":"31","author":"Montanez","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2022.12.005_bib5","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: from biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2022.12.005_bib7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2021.11.028","article-title":"Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network","volume":"162","author":"Petat","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.12.005_bib9","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.21037\/jtd-21-290","article-title":"The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review","volume":"13","author":"Song","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2022.12.005_bib10","article-title":"Correlation between the expression of PD-L1 and clinicopathological features in patients with thymic epithelial tumors","volume":"2018","author":"Chen","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ejca.2022.12.005_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.iotech.2019.09.002","article-title":"Immune checkpoints in thymic epithelial tumors: challenges and opportunities","volume":"3","author":"Girard","year":"2019","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.ejca.2022.12.005_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.12.005_bib16","doi-asserted-by":"crossref","first-page":"S1342","DOI":"10.1016\/j.annonc.2021.08.2147","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"32","author":"Girard","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.12.005_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100419","article-title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.12.005_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2022.12.005_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejca.2022.12.005_bib21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jclinepi.2014.03.003","article-title":"In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias","volume":"67","author":"Hunter","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2022.12.005_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","article-title":"Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis","volume":"4","author":"Ritchie","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.009","article-title":"Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: a retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group","volume":"174","author":"Antonarelli","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.12.005_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib25","article-title":"Lenvatinib for the treatment of thymic epithelial tumors (TETs): a real-life multicenter experience","volume":"40","author":"Benitez","year":"2022","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2022.12.005_bib26","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2022.12.005_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.12.005_bib28","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib29","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1038\/s41598-020-61053-8","article-title":"Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2022.12.005_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies","volume":"19","author":"Xie","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejca.2022.12.005_bib31","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thymic.pdf n.d."},{"key":"10.1016\/j.ejca.2022.12.005_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.005_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","author":"Conforti","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:47Z","timestamp":1760733587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"alternative-id":["S0959804922017932"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}